Real-World Study Backs Mepolizumab in Rhinosinusitis With Nasal Polyps

A recent Italian study has demonstrated the efficacy of mepolizumab in treating severe chronic rhinosinusitis with nasal polyps (CRSwNP). The research, led by Dr. Eugenio De Corso from the University of Perugia, showed that mepolizumab improved health-related quality of life and disease control for adults with severe CRSwNP.

At 12 months, the median nasal polyp score decreased significantly from a baseline of 6 to 3 on an 8-point scale (P < 0.0001). The Health-Related Quality of Life measure, the SNOT-22, also improved over the same period, dropping from a median of 59 to 21 at 12 months (P < 0.0001). These improvements were progressive over time, suggesting that clinical benefits may continue to increase beyond the initial phases of treatment.

About one in five patients experienced remission, defined by meeting the remission criteria without having completed the full 12-month duration. Disease control was achieved in 42% of patients at 12 months, with the potential for further improvement as 20% were on their way to remission. These findings contribute to the limited real-world evidence on the effectiveness of mepolizumab in CRSwNP, providing valuable insights for clinical decision-making.